omeprazole

GENERIC NAME

Romeo Victor M. Valderrama BSN-3A

Patients Initial: Date of Admission:

Age: CC:

Room: Attending Physician:

GENERIC NAME

BRAND NAME CLASSIFICATION MECHANISM OF ACTION INDICATIONS ADVERSE REACTIONSNURSING CONSIDERATIONS

omeprazole

210 g IVTT/ODPrilosecTherapeutic:

Antisecretory

Pharmacologic:

Proton pump inhibitorSuppresses gastric acid secretion by inhibiting the H+, K+-ATPase enzyme system [the acid (proton H+) pump] in the parietal cells.Duodenal and gastric ulcerGastroesophageal reflux disease including severe erosive esophagitis Zollinger-Ellison syndromeMultiple endocrine adenomasSystemic mastocytosisCNS:Headache, dizziness,asthenia, vertigo, insomnia, apathy, anxiety,paresthesias, dream abnormalities

Dermatologic:Rash, inflammation,urticaria,

pruritus, alopecia, dry skin

GI:Diarrhea, abdominal pain, nausea, vomiting,constipation, dry mouth, tongue atrophy

Respiratory:URI symptoms,cough,epistaxis

Other:Cancer in preclinical studies, back pain, fever

Assessment

History:Hypersensitivity toomeprazoleor any of its components; pregnancy, lactation

Physical:Skin lesions; reflexes, affect; urinary output, abdominal examination; respiratory auscultation

Interventions

Administer before meals. Caution patient to swallow capsules wholenot to open, chew, or crush them. If using oral suspension, empty packet into a small cup containing 2 tbsp of water. Stir and have patient drink immediately; fill cup with water and have patient drink this water. Do not use any other diluent.

WARNING:Arrange for further evaluation of patient after 8 wk of therapy forgastrorefluxdisorders; not intended for maintenance therapy. Symptomatic improvement does not rule out gastric cancer, which did occur in preclinical studies.

Administer antacids withomeprazole, if needed.